AB Science Release: European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec® Resistant Gastro-Intestinal Stromal Tumor

Published: Oct 04, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for masitinib in the treatment of patients with Gleevec®-resistant gastro-intestinal stromal tumors (GIST).

Back to news